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ForEword By MINISTEr For ENTErPrISE, TrAdE ANd EMPloyMENT 
MIchEál MArTIN T.d.
I am delighted to welcome this report of the Advisory Science council. The council is a key  
element of the new coordination and governance structures for STI initiated by the  
Government in 2004 and 2005. what the council adds, critically, is the stakeholders’ input,  
without which the range of advice, information and consultation available to Government  
would be incomplete.
As such, the council plays a key role in the implementation and monitoring of the Government’s 
new Strategy for STI, which we launched on 18 June this year. Following the launch, the chair of 
the Advisory Science council and I, together with other panel lists, engaged in a presentation on 
and discussion of the STI Strategy with key stakeholders in enterprise and academia, during which there was a strong 
commitment to the task ahead in order for us to see Ireland fully realise it’s objective of becoming a strong, vibrant 
knowledge economy.
with publication of this important report on health research, we see one of the first outputs of the whole of Government 
approach to the STI agenda, which we have been promoting. This bodes well for the continued implementation of the 
strategy and this new ‘joined up’ approach, which we believe will deliver more coherent and effective STI policies, leading 
to overall improvement in social and economic well-being.
health is a clear example of where the Government’s sectoral policy objectives and economic objectives are mutually 
supportive and reinforcing. Major improvements in health care are being, and will be, achieved through advances 
in science and medicine and through developments in areas such as biotechnology and genetics. Agencies of my 
department, namely SFI, EI and IdA, are all working with a range of other bodies in the health-related sector to ensure 
Ireland captures our full potential in this growing area.
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on behalf of the cabinet committee on STI, which I chair, and on behalf of the Interdepartmental committee on STI lead 
by my department, I would like to thank the ASc for taking on this critically important work on the potential for health 
research. I know they have engaged in a wide-ranging consultation with industry and the health sector, with patient 
groups and with enterprise, thereby working to achieve a balance between the objectives of improving the health of the 
population and repositioning Ireland as a location for the best researchers and the best research, whether in the public or 
private sectors. There are benefits for all here and I hope that everyone concerned grasps the many opportunities set out 
in this report, so that these benefits are realised to the full.
Micheál Martin, T.d.
Minister for Enterprise, Trade and Employment
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PrEFAcE By MINISTEr MAry hArNEy T.d.,  
MINISTEr For hEAlTh ANd chIldrEN
I wish to thank the Advisory council for Science, Technology and Innovation for its initiative in 
conducting this review of health-relation research. In issuing the Strategy for Science, Technology 
and Innovation earlier in the year the Government recognised the need for a major increase in 
research activity both to maintain the country’s economic competitiveness and to improve the 
wellbeing of the population and health care is a prime example of the latter.
The Government has recently completed a major structural reform of the health care system 
with a view to improving health outcomes for the nation. research also has a major role to 
play in improving health outcomes but because of other pressures on the system it has not been afforded the priority it 
deserves. It is a key element of the system spanning population health, services research, translational research as well as 
fundamental scientific discoveries. The department of health and children is central to developing policy in this area and 
has been strongly supported by the health research Board. The legislation governing the health Service Executive and the 
health Information and Quality Authority now gives these two agencies a clear role in research and this should provide a 
much needed boost to the health research community.
health research and development are key elements for the improvement of the health of the population, not just in the 
context of the insights and discoveries it provides, but also in attracting to the Irish health care system practitioners of the 
highest calibre and ensuring that we have the quickest possible access to new innovations.
This review is very timely and I am particularly pleased that the task force who prepared it consulted with a range of 
patient and community groups. It sets out a significant agenda and I and my department will be working with the other 
Government departments and the health agencies to progress the actions outlined.
Mary harney, T.d.
Minister for health and children
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eXecUtive SUMMaRY
BacKgROUnd
as part of its work programme for 2006, the advisory council for Science, technology and innovation has examined 
the area of health-related research. the council adopted a broad definition of health-related research, covering the  
full spectrum of research from basic/frontier science in a broad range of disciplines and translational research, through 
clinical research, clinical trials and health services/systems research, to research on the determinants and promotion  
of health in the population. it also considered health-related research and its application across a range of industry 
sectors including pharmaceuticals, medical technologies, food and the environment.
during its deliberations, the council identified a number of issues that need to be resolved in order to ensure 
that science, technology and innovation make their maximum contribution to the irish health care system, to the 
population as a whole, and to health-related industry operating in ireland. these issues are complex, and do not lend 
themselves to simple resolution.
the pOtential OF health-Related ReSeaRch: What We can achieve
the potential benefit of basic biomedical, translation, health services and population research for the country is very 
significant, specifically leading to improved health outcomes for people. the council's ambition is to suggest how 
ireland might realise that potential.
the council's vision is to drive a step change in the level and quality of health-related research and innovation 
in ireland – both to enhance the health of the irish population and to capture in ireland the benefits of effective 
commercialisation of the intellectual property created.
a key element of this vision is to equip clinicians with the knowledge, experience and environment to deliver the best 
possible health care, based on the latest therapies and technological developments worldwide. involvement of the 
health system in research is one of the most effective means of ensuring that it is open to and is applying the latest 
developments in health care, management and practice. a secondary benefit will be to increase the numbers of highly 
trained researchers and technicians who will enhance national competitiveness in attracting health care research 
industries to ireland. the goal is to make ireland the destination of choice when advanced technology for health is 
being conceived, tested or implemented.
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RealiSing the pOtential: hOW We can achieve it
this review is the outcome of a rigorous consultation and review process that concentrated on establishing 
how ireland's considerable potential for health research might be realised. the report includes a number of 
recommendations on how the challenges facing the health research sector might be met by policy makers, 
implementation bodies, hospitals, universities, and enterprise.
national health Research policy and Strategy
ireland needs an integrated, coherent policy on health research, and this needs to be developed into a national strategy 
that has the support and commitment of government, the educational system, the research bodies, the hospitals, the 
medical and health professions and other stakeholders. increasing the performance and exploitation of health research 
represents a major opportunity to contribute to the development of the knowledge economy in ireland. however, the 
national health research strategy needs to be developed and implemented as a matter of urgency as the window of 
opportunity is limited.
Up to now there has been a diffusion of responsibility in the area of health research policy. the council sees great 
value in consolidating the policy and strategy function to an assistant Secretary designated as head of health Research 
policy within the department of health and children to provide leadership in this area.
Other steps towards making policy and strategy more coherent include the establishment by the department of  
health and children of a cross-departmental/agency health Research group under the auspices of the 
interdepartmental committee for Science and technology (idc) – to identify and clarify policy priorities in a timely 
way, to coordinate the work of various government departments in this area and to achieve coherence across the 
health system in relation to research.
in addition, the heath Research group should be supported by a time-limited expert advisory group to advise on 
strategic priorities and funding requirements. a Forum of Stakeholders should also be established, including enterprise 
and patient groups, to ensure ongoing dialogue with policy makers.
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integrated governance
international best practice for health research integrates the work of academia and hospitals, and uses the combined 
resources of both. in this model, research is conducted under the leadership of clinically trained academic scientists 
who have clinical time in the hospitals. Up to now, such a model has not been widely adopted in ireland, and there is 
a disconnect between the universities and the hospitals.
For ireland to optimise the social and economic returns from research, the council believes that clearer governance 
structures need to be developed between hospitals and universities, and that incentives should be offered to reward 
hospital-university interaction and the integration of research and clinical practice.
Funding
Funding for health-related research comes from a wide range of public and private sources, and the total current 
expenditure while significant, is low by international comparisons. the council sees a requirement to ensure that the 
particular health research needs of the irish population are addressed by top-quality, adequately-funded research, 
both through the budget of the department of health and children and under the government‘s Strategy for Science, 
technology and innovation, 2006-2013.
Significantly increased investment is needed in health research and this should be coordinated across all funding 
agencies, including Science Foundation ireland, the health Research Board, the higher education authority, and 
enterprise ireland. in particular, excellence, endorsed by peer review, and relevance in terms of contribution to 
ireland‘s population and enterprise priorities must remain the key criteria for the awarding of funding.
human capital, education and infrastructure
to build critical mass in health research, ireland needs to recruit increased numbers of clinical researchers with 
protected time for research and dedicated support staff. Significant investment in research and key infrastructure will 
help attract the most talented people into research and clinical practice. attractive career structures and incentives for 
researchers to stay in the health research system need to be developed.
change is also required in the way health professionals are educated, with considerably more exposure to research 
methods and experience for both undergraduates and postgraduates.
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Finally, investment is required to address the current infrastructure gaps in translational and clinical research.  
the introduction of a unique patient identifier and electronic patient records is an essential pre-requisite to  
harnessing the full potential of research for improved patient care and should be done through a clear and  
transparent framework.
innovation, Regulatory affairs and translation
hospitals, historically, have not placed a significant emphasis on research and have not integrated it into their core 
mission. consequently, the opportunities for linking with industry and developing and translating intellectual property 
(ip) into new diagnostics, devices and therapies have not been taken. the council believes that hospitals need to 
develop research strategies and to integrate research as a clearly-stated component of their mission. hospitals should 
work with the universities' technology transfer offices to develop procedures to ensure ip is effectively captured, 
protected and exploited.
the approvals process for clinical trials currently operating in ireland is fragmented, slow and under resourced. the 
council recommends that this process should be substantially streamlined and professionalised – in particular through 
the consolidation and professionalisation of ethics committees and the development of a co-ordination mechanism by 
the department of health and children. parallel regulatory and ethical review of clinical trial applications should be 
standard practice and the provision for electronic submissions should be enabled with immediate effect.
Finally, the council believes that there are substantial opportunities for ireland in the area of translational research, 
as researchers seek to bring new basic research findings to the patient and industry brings new equipment and 
therapeutics to the market. to develop as a centre of excellence for translational research will require that ireland has 
the infrastructure and expertise in place, that approval structures are efficient and transparent, that the mechanisms 
to translate research to the commercial sector are clear, accessible and effective and that State support and hospital 
– higher education institutional policies are coordinated. the areas for ireland to prioritise need to be identified and 
targeted by ida ireland, enterprise ireland and the other funding agencies and built into the national strategy for 
health research.
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SUMMaRY OF RecOMMendatiOnS
natiOnal health ReSeaRch pOlicY and StRategY
R1 designate an assistant Secretary as head of health Research policy in the department of health and 
children. the appointed person should be supported by a principal Officer with responsibility for research and 
appropriate policy development staff and the expertise of the health Research Board, health Service executive 
and health information & Quality authority.
 Research functions of the health Research Board, the health Service executive and the health information & 
Quality authority should be accountable to and coherence ensured by this person.
Responsibility: department of health and children
R2 establish a health Research group under the auspices of the idc, comprising department of enterprise, trade 
& employment (dete), department of education & Science (deS), department of environment, heritage & local 
government (dehlg), and the department of agriculture & Food (daF), supported by their agencies including 
the hSe, hRB, hiQa, SFi and ei. the group should be chaired by the department of health and children. this 
group should be mandated to formulate in a timely way and oversee implementation of a national health 
research policy and strategy, including health services research and epidemiology with clearly defined 
objectives and priorities as a matter of urgency.
 an international expert advisory group should be appointed to undertake a comprehensive review of health 
research priorities, and advise on strategic research and funding priorities for ireland.
 establish a health Research Forum of stakeholders to facilitate ongoing dialogue among the health research 
community and with the health Research group.
Responsibility: idc on Sti, department of health and children, hSe
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integRated gOveRnance
R3 develop clear and transparent governance structures between hospitals and universities.
 in the case of selected major teaching hospitals, a single governance model between the hospital and its 
associated university should be explored.
 incentivise and reward interaction between teaching hospitals, other health care and health research settings 
and associated universities.
Responsibility: hSe, hospital ceOs, University presidents,department of health and children
R4 promote academic leadership of research and the integration of research and clinical practice.
Responsibility: hospital ceOs, health Service executive
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FUnding
R5 Funding for health research should be increased in line with that in similar benchmarked health systems.
Responsibility: department of health and children, hSe, health Research group
R6 department of health and children to develop a transparent, coherent and efficient structure for the promotion, 
funding and commissioning of health research in between hRB, hSe and hi Qa.
Responsibility: department of health and children
R7 expand the remit of Science Foundation ireland to include certain aspects of translational research relevant to 
its funded research.
Responsibility: Science Foundation ireland 
R8 Research funding bodies to further develop joint strategies and hold joint calls and co-fund health research 
initiatives to ensure continuity of research from bench to bedside. Fully exploit the potential for international 
networking and leveraging funding for health research under the eU’s Seventh Framework programme for 
Research, 2007-2013. actively promote foundation and philanthropy funding for health research.
Responsibility: health Research Board, Science Foundation ireland, enterprise `ireland, ida, higher education 
authority, department of agriculture & Food, Medical Research charities
R9 allocate funding on the basis of excellence, as endorsed by peer review, and relevance.
Responsibility: all funding agencies
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hUMan capital, inFRaStRUctURe and eQUipMent
human capital
R10 Recruit increased numbers of clinicians with protected time for research.
 Recruit increased numbers of nurses, allied health professionals, epidemiologists, social and behavioural 
scientists with protected time for research. ensure that other research support staff are available.
Responsibility: health Service executive, hospitals, Universities
R11 devise a range of incentives, including attractive career structures to attract both clinical and non-clinical staff 
to pursue research careers. in particular, efforts should be made to attract researchers from abroad in key areas 
where ireland is seeking to build a critical mass of excellent research.
Responsibility: health Service executive, hospitals, Universities, health Research group
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education of health professionals
R12 Undergraduate and postgraduate medical training to include exposure to research methods and experience.
 new courses to be introduced including: MB phd; postgraduate courses in translational research; clinical 
epidemiology; nursing research methodology; and cross-disciplinary studies.
 Medical schools to collaborate in the development of undergraduate and postgraduate courses to ensure 
delivery to the highest international standards.
 international mobility, supported by the health Service executive, to be an integral part of these programmes.
 establish a national graduate school in translational medicine linked to a network of clinical research centres.
Responsibility: Medical Schools in conjunction with universities, hospitals and training bodies
R13 develop postgraduate training tracks for academic clinicians and continuing professional development  
for physicians.
Responsibility: Medical Schools in conjunction with universities and hospitals
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infrastructure and Facilities
R14 develop a research investment plan setting out the immediate additional investment required in key 
infrastructure to facilitate effective translational research and the infrastructural investment requirements to 
address strategic national priorities.
 prioritise the introduction of an integrated electronic medical records system and unique patient identifier, 
based on appropriate public consultation.
Responsibility: health Research group
innOvatiOn, RegUlatORY aFFaiRS and tRanSlatiOn
innovation
R15 Research to be a clearly stated component of the mission of academic teaching hospitals and of the health 
Service executive.
 each teaching hospital to have a research strategy.
Responsibility: teaching hospitals, health Service executive, health Research Board
R16 institutional ownership of ip arising from publicly funded research to be asserted through hospital policies and 
consultant contracts.
Responsibility: employer – health Service executive/hospitals and/or Universities
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R17 a number of actions are required to promote the commercialisation of health related research. hospitals  
to establish procedures to capture, protect and exploit intellectual property.
 hospitals to work with technology transfer offices in affiliated universities to make best use of available 
capabilities and to exploit ip optimally.
 enterprise ireland to provide additional technology transfer expertise in health, pharmaceutical and medical 
technology research – to hospitals through the universities.
 a central portal to facilitate industry, academic, hospital collaboration to be established.
Responsibility: hospitals with University technology transfer offices and enterprise ireland
R18 Foster innovation and excellence in primary care, health services and population health research.
Responsibility: health Service executive
R19 Outreach initiatives to be introduced to raise awareness of the importance of research in improving health 
service delivery, patient care and population health and the role of industry in timely translation of research 
outcomes to innovative products and therapies.
Responsibility: health Service executive, hospitals, Universities, health Research Board
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Regulatory affairs
R20 Streamline and consolidate ethical approval structures to four regional ethics committees, with professional 
paid members, sectoral specialists, standard operating procedures and well resourced secretariat.
 department of health and children to establish a coordination mechanism for this revised ethics committee 
structure and this should be the first contact point for enterprises and academics wishing to conduct a trial. 
 enable electronic submissions of applications for clinical trails approvals with parallel review by the irish 
Medicines Board and ethics committees as standard practice.
Responsibility: department of health and children, irish Medicine Board
promoting and developing capability in translational Research
R21 identify the specific areas of translational research where ireland can develop a leading position and the 
actions required to differentiate ireland as a location of choice for translational research.
Responsibility: ida ireland, enterprise ireland, hRB, health Research group
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1 intROdUctiOn – WhY health ReSeaRch  
iS iMpORtant
the potential benefit of health-related research to the social and economic well-being 
of the population is very significant. the results of health related research play a 
major role in people living longer and healthier lives; in increased productivity and 
improved health outcomes; and in reducing the burden of disease on society.
investment in health-related research can yield returns in a number of ways – for 
example, through:
• the improved health, wellness and quality of life of the general population and 
reduced social and economic inequalities in health,
• improved diagnosis, disease prevention, patient care and treatment,
• better trained and educated health-care workers,
• better diagnostic tools, medical devices and more cost-effective treatments, 
and
• more efficient use of skilled personnel, scientific and clinical infrastructure, and 
other resources.
patients, professionals and the healthcare system can be affected positively by 
involvement in health research. patient care is optimal when clinical trial activity is 
present. patients involved in clinical trials can benefit from access to new treatments 
in advance of market authorisation and drugs that are in short supply when first 
manufactured are prioritised to clinical trial sites. if ireland embraces clinical research, 
our health service professionals will be trained and supported to bring innovations to 
ireland as a first adopter of new ideas. Without this, and, given our small market size, 
ireland will not be a priority country for new therapies.
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health Research 
dramatically improves 
peoples lives
patient awareness and involvement in research are therefore critical to establishing a 
vibrant research environment in ireland. central to fostering a willingness of patients 
to engage in the research process are outreach activities and public communication on 
past and potential impacts of research, on current and strategic areas of investigation, 
on emerging research findings and their potential future influence on treatments, and 
on the role of industry in translating research into clinical practice.
all clinical trials involve some element of risk, and there is a need to have strong 
and robust ethical and regulatory environments to support a research-oriented health 
system where risk is minimised. equally, patients need to have access to clear and 
unambiguous information to support their choices when considering participation in 
health research and clinical trials.
health research can also contribute to the further development of the knowledge 
society with consequent economic benefits. the domestic healthcare sector is a very 
significant component of the irish economy, currently accounting for 10% of jobs.1 
Fourteen of the world's top fifteen pharmaceutical companies and fifteen of the top 
twenty-five medical technology companies have operations in ireland. pharmaceutical 
exports amounted to €23 billion in 2004. exports from the medical technologies 
sector reached €5.5 billion in 2004 with over 23,000 employed. in the same year, 
ireland supplied 24 per cent of US imports of biotechnology and 36 per cent of US 
imports of life sciences products2.
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1  cSO, database direct.
2  national Science Foundation, national Science Board, Science and engineering indicators 2006, volume 1.
health Related 
Research Underpinning 
economic growth
taBle 1  SaleS, eXpORtS, eMplOYMent and R&d in health Related SectORS, 2004
 Sales (€m) exports (€m) employment R&d spend (€m)
chemicals/pharmaceuticals 23,692.00 23,015.20 25,211 261.40
Medical devices/instruments 5,867.40 5,545.30 23,583 100.00
Source: Forfás, annual Business Survey of economic impact (aBSei) and employment data.
industry has a critical role to play in translating new research findings into innovative 
products, processes and techniques and in ensuring that research outcomes are 
translated into patient benefit and improved health outcomes as quickly and 
efficiently as possible. a highly competent and efficient regulatory environment is 
vital to ensure that the application of new knowledge benefits irish people quickly, 
while ensuring the safety of new products through the most stringent ethical and 
safety standards.
innovation is as important in health services delivery as in any other sector. in 
addition to improving patient outcomes, it also serves to drive down costs and to 
increase the productivity of the sector. evidence from research spanning prevention of 
ill-health, disease and condition management, patient care, delivery of healthcare and 
its organisation, as well as public health and social care is essential to underpinning 
innovation and continuous improvement in the health service.
health services and patient related research is complex and academic excellence 
from many disciplines is required to collaborate with practitioners and patients. 
For example, it is care delivery structures and processes at the condition level that 
translate new medical knowledge and technology into improved patient outcomes, 
while also contributing to new knowledge. harnessing this potential requires close 
partnership and linkage across the full spectrum of health related research and 
among all professionals with a role in conducting and enabling health research. in 
this context, other developed countries are seeking to promote, stimulate and nourish 
research collaborations that bridge biomedical science, health systems and services, 
and population health research, incorporating multiple health research perspectives.
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2 viSiOn FOR iReland
the council's vision is to drive a step change in the level and quality of health 
research, to enhance the health and wellness of the population, and to build an 
international reputation for ireland in health research through excellence  
and innovation.
Key elements of the vision are to:
• provide the evidence base for policies to promote positive health in the 
population and reduce the burden of illness and premature mortality,
• provide the best possible health care for our people by using the latest 
therapies and technological developments,
• build a well-funded vibrant health research system to attract top-class clinical 
and biomedical researchers, and
• position ireland as a leading location for the performance and 
commercialisation of health research.
in conducting its review, the council adopted a broad definition of health-related 
research, covering the full spectrum of research from basic/frontier science in a broad 
range of disciplines and translational research, through clinical research, clinical 
trials and health services/systems research, to research on the determinants and 
promotion of health in the population. it also considered health-related research 
and its application across a range of industry sectors including information and 
communications technologies (ict’s) pharmaceuticals, medical technologies, food and 
the environment.
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Step change needed in 
irish health Research
FigURe 1  RelatiOnShip BetWeen diFFeRent eleMentS OF the health ReSeaRch SYSteM
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3 KeY challengeS and RecOMMendatiOnS
3.1 natiOnal health ReSeaRch pOlicY and StRategY
national health Research policy and Strategy: challenges
in 2001, the department of health and children published Making Knowledge Work for 
health, a detailed strategy that addressed the lack of coherence and strong leadership 
in the formulation of health research policy and set out a clear health research agenda. 
Some progress has been made in implementing the recommendations of the strategy 
but a number of significant gaps remain as the implementation of the strategy was 
overtaken by the structural reform of the health service. in addition, the environment 
for health research in ireland has changed considerably since the publication of this 
strategy. there is an increasing willingness among health-related industries to engage 
in R&d in ireland; but there is also increasing competition from other countries seeking 
to develop their health systems as a major resource for research and economic 
development. Structural changes to the environment for health research include:
• the launch of the health Reform programme in 2003.
• the establishment of the health Services executive in 2005.
• the impact of Science Foundation ireland's considerable investment in basic 
biomedical research and its potential applications in the health area, since  
its establishment.
• the government's recently announced Strategy for Science, technology and 
innovation, 2006-2013.
changing 
environment for 
health Research
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the council's review provides an opportunity to build on Making Knowledge Work  
for health, reinforcing the key messages that remain relevant and making further 
recommendations to significantly strengthen health research in ireland. today in 
ireland there are clear and defined mechanisms to review and integrate sectoral 
strategies such as that outlined in Making Knowledge Work for health into the  
overall R&d framework for ireland.
While the department of health and children have overall responsibility for health 
research policy, and its agencies and the health Service executive have specific remits 
in relation to research, a number of other government departments are currently 
involved with health-related research policy and funding, either directly or through 
their executive bodies and agencies. these include:
• the department of education & Science,
• the department of enterprise, trade & employment, and
• the department of agriculture & Food.
health research also presents opportunities for the department of communications, 
Marine & natural Resources and the department of environment, heritage &  
local government.
this diffusion of responsibility means that decisions relating to health research  
are made independently, without strategic direction or reference to agreed national 
priorities. in this context, efforts may be duplicated – with consequent inefficient 
use of resources – and areas of specific national need or opportunity might not  
be addressed.
diffusion of 
Responsibility
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although executive agencies play a crucial role in funding and developing health 
research, there is a need for an overarching policy framework to be developed and 
agreed at government level. at present there is no clear leadership at national 
level, with no dedicated person or 'champion' with responsibility for achieving 
coherence and coordinating the national health research agenda which is limiting the 
potential for health research in ireland to enhance patient care and lead to economic 
development. in other countries (such as the United Kingdom and israel) where 
health research and services delivery are well integrated, directors for health research 
have been appointed to lead health research policy development and achieve 
coherence across government departments.
With the establishment of the health Services executive, the department of health 
and children now focuses on broad policy development, and this presents an 
opportunity for a significant strengthening of the health research policy capacity of 
the department of health and children. as the hSe has responsibility for all executive 
functions it has a key role to play.
establishing clarity and leadership in health research policy will place ireland in a 
better position to connect internationally with leading centres on policy and strategy 
including an all island dimension. as northern ireland is part of the UK system, it has 
a well structured health research system with many opportunities for joint initiatives 
to improve health outcomes on the island and build critical mass in research.
international links
leadership to integrate 
health Research and 
Services delivery
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national health Research policy and Strategy: Recommendations
ireland needs a coherent policy on health research that integrates the key elements 
and strategies of the national innovation system, including the educational system, 
the research bodies, the hospitals, enterprise, non-governmental organisations, the 
medical and health professions and other health researchers and that has the support 
and commitment of government.
health research requires clear policy leadership at national level. international best 
practice is for governments to appoint a director of health research3 in the ministry 
for health, with ultimate responsibility for providing leadership in the development of 
health research. ireland needs to similarly overhaul its approach to developing health 
research policy and develop the capacity for health research policy formulation.
in ireland, the department of health and children should continue to have primary 
responsibility for health research policy and lead in the development of a coherent 
policy for health research, both within the department and at a trans-departmental 
level. this responsibility should be headed at assistant Secretary level in the 
department of health and children.
R1 designate an assistant Secretary as head of health Research policy in the 
department of health and children. the appointed person should be supported 
by a principal Officer with responsibility for research and appropriate policy 
development staff and the expertise of the health Research Board, health 
Service executive and health information & Quality authority.
 Research functions of the health Research Board, the health Service executive 
and the health information & Quality authority should be accountable to and 
coherence ensured by this person.
Responsibility: department of health and children
3  in the case of the UK the director of health Research and development, professor Sally davies is located in the department of 
health, having previously held a position in the nhS.
clear policy 
leadership
22
health research policy formulation requires coordination across a range of government 
departments. the council recommends that the department of health and children 
arrange for the establishment of a new inter-departmental/agency health Research 
group to identify and clarify policy priorities in a timely way and to facilitate a 
coherent cross-departmental and cross-agency approach. as it will have oversight of 
the activities of a range of government departments and agencies it requires to be 
chaired by the department of health and children. 
the health Research group should be charged with formulating and implementing a 
comprehensive health research strategy.
For this health Research group to operate effectively, each department and agency 
represented on it will need to allocate resources to it, and designate at least one 
person with competence and capability in the area of health research policy.
the health Research group should work closely with the development agencies in 
formulating the strategy and seek input and advice from the new chief Scientific 
advisor on certain issues.
the timeframe for implementation of the strategy is critical. clearly defined objectives 
and a defined implementation schedule are imperative. the window of opportunity 
is limited and ireland needs to act quickly to remove barriers and build its reputation 
as a competitive location for health research performance in order to maximise the 
potential opportunity in the translational research field.
co-ordination 
across government 
departments
national health 
Research Strategy
need for 
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the identification of strategic research priorities and development of an investment 
plan are key elements of a comprehensive health research strategy. the council 
recommends the establishment of an international expert group to advise the health 
Research group on research and funding priorities for ireland.
the expert group would meet for a limited period (six to nine months), and would 
comprise between six and ten active funded international researchers and research 
managers from industry and academia, across a range of disciplines and different 
elements of the health research system from fundamental biomedical research to 
population health, with a chairperson from the irish health research system. the group 
should also consider the implications of its recommendations on national skills4 and 
infrastructure requirements. it could be envisaged that subsequent expert groups 
would be established from time to time by the health Research group to advise on key 
strategic issues as they arise.
4  the group should liaise with the expert group on Future Skills needs in this regard. 
defining Research and 
Funding priorities
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the ongoing exchange of information amongst the health research community and 
with health research policy makers is another key requirement for cohesive, informed 
policy development. the council recommends the establishment of a health research 
forum with broad and inclusive representation of stakeholders with an involvement in 
health research.
the Forum would also provide input to the determination of strategic funding 
priorities through the expert group and contribute to subsequent expert groups  
as appropriate.
R2 establish a health Research group under the auspices of the idc, comprising 
department of enterprise, trade & employment (dete), department of 
education & Science (deS), department of environment, heritage & local 
government (dehlg), and the department of agriculture & Food (daF), 
supported by their agencies including the hSe, hRB, hiQa, SFi and ei. the 
group should be chaired by the department of health and children. this group 
should be mandated to formulate in a timely way and oversee implementation 
of a national health research policy and strategy, including health services 
research and epidemiology with clearly defined objectives and priorities as a 
matter of urgency.
 an international expert advisory group should be appointed to undertake a 
comprehensive review of health research priorities, and advise on strategic 
research and funding priorities for ireland.
 establish a health Research Forum of stakeholders to facilitate ongoing 
dialogue among the health research community and with the health  
Research group.
Responsibility: idc on Sti, department of health and children, hSe
health 
Research Forum
FigURe 2  RecOMMended StRUctUReS FOR develOping health ReSeaRch pOlicY and StRategY
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3.2 integRated gOveRnance
integrated governance: challenges
international best practice in health research integrates and uses the combined 
resources of academia, hospitals and other health agencies including those based 
in the community. in this model, clinical and translational research is conducted 
under the leadership of clinically trained academic scientists who also have clinical 
responsibilities in the associated hospitals. Strong and clear links between academic 
hospitals and universities can serve as an important mechanism for ensuring that the 
priorities of the health system are reflected in the research agenda, and that new 
research findings quickly find their way into clinical practice and the education of 
health professionals. in parts of the United States, for example, the university owns 
the teaching hospital. this academic leadership and concentration of resources works 
to the benefit of patients, ensures that the research conducted is relevant to the real 
needs of patients, and that research results more readily inform clinical practice.
currently, with a few notable exceptions, connections in ireland between universities 
and their associated hospitals are not formalised or achieving their potential. 
Strengthening and formalising the links between universities and hospitals and  
across hospital academic and service delivery functions can bring a number of real 
benefits, including:
• optimising the research focus,
• beginning to harness the impact of research on clinical practice,
• optimising human resource deployment, administration and the use of physical 
facilities, and
• maximising the impact of new R&d for irish patients and the healthy  
population alike.
integrating and 
combining Resources
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also, given ireland's small size, to build critical mass in translational and clinical 
research will require universities, hospitals and clinical research centres to cooperate 
and function as a single cohesive research unit. areas for enhanced cooperation on an 
all-island basis should be explored. 
to ensure that leading edge science and the latest research findings impact on 
healthcare in ireland and that health research has relevance to the irish population,  
it is essential that the academic leadership of medicine is empowered amongst 
clinicians in hospitals and that the clinical departments become integrated with 
university-based departments of basic research in driving translational and clinical 
research. it is such academically appointed healthcare professionals who are best 
positioned to understand unmet clinical needs and the potential for research to drive 
developments in diagnostics, therapeutics and ict which could impact on human 
health and disease.
developing the culture of innovation and learning in hospitals is essential in this 
regard. Research contributes to the development of medicines and therapies which 
enhance wellness and improve the prevention and treatment of disease globally. it 
can also contribute to the understanding and treatment of conditions and diseases 
that are of specific relevance to the irish population, thereby enhancing quality of 
life and lessening the burden on the health service. the council is also aware that a 
significant proportion of health research occurs at the interface between the hospital 
and primary/community care and at the interface between the health and social 
sciences. there is therefore a clear need to develop governance structures that reflect 
the range and diversity of health research in ireland.
developing a 
culture of innovation 
and learning
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integrated governance: Recommendations
the council recommends the establishment of clear and transparent governance 
structures between hospitals and universities, underpinned by clear and explicit 
legal agreements which identify and regulate areas such as joint appointments, 
career structures, budgetary arrangements and mechanisms to manage and exploit 
intellectual property. the current directorate structures in hospitals should have clear 
relationships with the academic structures within the universities. hospitals that 
implement such structures should be rewarded by an increased budget allocation.
the council also recommends that, over the longer term, consideration should be 
given to developing a single governance model for teaching hospitals and their 
associated universities – a model which may be appropriate for a small number of 
major academic medical centres in the country.
University hospital 
governance Structures
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collaboration and interaction between universities and associated teaching hospitals 
should be encouraged. hospitals should be incentivised financially to actively engage 
in research and to build their own research capacity, either directly through research 
overheads or through budgetary structures.
R3 develop clear and transparent governance structures between hospitals  
and universities.
 in the case of selected major teaching hospitals, a single governance model 
between the hospital and its associated university should be explored.
 incentivise and reward interaction between teaching hospitals, other health 
care and health research settings and associated universities.
Responsibility: hSe, hospital ceOs, University presidents,department of health 
and children
the council recommends promoting academic leadership of research and the 
integration of research and clinical practice within hospitals and other healthcare 
settings. the ongoing review of consultants' contracts provides an opportunity for  
the implementation of changes in the governance structures of academic and service 
delivery functions that will be necessary to realise this objective.
the review of consultants' contracts also presents the opportunity to populate 
academic departments in hospitals through which research resources should  
be channelled.
R4 promote academic leadership of research and the integration of research and 
clinical practice.
Responsibility: hospital ceOs, health Service executive
academic leadership 
of Research
integrating Research and 
clinical practice
collaboration and 
interaction
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3.3 FUnding
Funding: challenges
the health Research Board, which is an executive agency of the department of health 
and children, has statutory responsibility to promote, commission and conduct health 
research and is the main funder of health research.
however, funding for health-related research comes from a number of additional 
public and private sources, including the following:
• Science Foundation ireland (Science Foundation ireland),
• enterprise ireland (ei), 
• the higher education authority (hea), programme for Research in third-level 
institutions (pRtli),
• irish council for Science, engineering and technology (iRcSet),
• irish council for humanities and Social Sciences (iRchSS),
• the european Union Framework programme,
• the Medical Research charities group (MRcg), and
• the Wellcome trust.
While the hea’s and SFi's remits are broader than health research, recent significant 
investment in infrastructure through pRtli and in fundamental bioscience through SFi 
has been of significant benefit to the health research system.
Stepping up 
translational and 
clinical Research
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By investing heavily in fundamental bioscience, SFi has significantly strengthened the 
capacity in frontier biotechnology research, much of which has potential applications 
in human health. through the pRtli and SFi initiatives, the university sector now 
has world-class infrastructure to conduct research and can attract high calibre 
internationally renowned researchers. the initial rounds of pRtli have focused heavily 
on laboratory-based bioscience and biomedicine infrastructure. indeed, 49 per cent 
of pRtli expenditure has gone to develop infrastructure in this area which is largely, 
but not exclusively on university research sites. now that there is a critical mass of 
fundamental research, it is appropriate to develop the logical progression of this 
research portfolio into translational and clinical research.
the challenge is to ensure that both the funding and the infrastructure are in place 
to ensure that investment in basic research can be translated to improved patient 
outcomes and increased health of the population and into effective and marketable 
diagnostics, devices, pharmaceuticals and information technologies. currently 
in ireland, excellent translational science is sometimes truncated at pre-clinical 
study stage, with consequent loss of opportunity for health and economic benefit. 
investment in fundamental research now needs to be complemented by investment 
in translational and clinical research capability.
ireland’s total expenditure on health research in the higher education Sector in 2004 
was approximately €90m (Forfás Survey of Research and development in the higher 
education Sector 2004). While this is a significant sum, it is small when compared with 
US universities or indeed the research budgets of individual pharmaceutical companies. 
For example, the University of pennsylvania spends approximately $500 million a year 
on biomedical research; and the annual R&d budgets of the top five pharmaceutical 
companies range from €1.0bn to €5.5bn. also, by comparison with other countries 
with which we compete, health research remains under-funded in ireland. Research 
funding accounts for 1.0 per cent5 of the €12.5bn total health vote in the estimates for 
2006. in the UK, by contrast, funding for health research through the Medical Research 
council and through the national health Service R&d programme is well in excess of  
5  State expenditure on Science and technology 2005, Forfás (background data).
competing demands: 
Making choices
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£1 billion per annum, at approximately 1.6 per cent of the nhS's total budget. in 
addition, the British government announced (in december 2005) a major investment 
programme in R&d through the nhS over the next five years.
Moreover, the range of scientific and technological disciplines involved in health-
related research is very broad, as is the range of new knowledge, techniques and 
products becoming available. there are competing demands for funds – between 
meeting the day-to-day needs of the health system and the need to increase funding 
for health research and other areas.
We need to ensure that the particular health research needs of the irish population 
are addressed by top-quality, adequately resourced health-related research in 
ireland. and this needs to be complemented by the ability to identify and exploit 
new knowledge, techniques and products, whatever their source. Strategic research 
aligned with population needs and the industry base must be supported along with 
continuing support for bottom-up investigator-driven research.
it is immediately apparent that ireland – a small country, with limited resources – will 
have to make choices about how much research to support and in which particular 
areas. the funding currently being provided is insufficient to remove the infrastructure 
and human capital deficiencies that are blocking ireland from harnessing the full 
potential of health research. additional funding will need to be prioritised within the 
health budget and through the securing of required funding under the government’s 
national development plan, 2007-2013 for sectoral research priorities.
there is also a need for the health Service executive to proactively encourage, 
facilitate, commission and provide funding for health research in areas of relevance to 
the irish population, the irish health system and irish economic development.
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the proposed idc health Research group needs to set research and funding priorities 
and develop a coherent trans-departmental funding strategy. this should cover the 
full spectrum of health research from fundamental biotechnology, translational and 
clinical research to health services and population health research; and it should take 
into account advice provided by the expert group. 
in addition, the department of health and children, together with the hSe, hRB 
and hiQa will need to develop an efficient and transparent mechanism for the 
promotion, funding and commissioning of research from basic biomedical though to 
health services and epidemiological research and in the context of the activities of 
other funding agencies such as Science Foundation ireland and the higher education 
authority. there are a number of options that can be considered. While a single 
funding agency for health research in general was considered to have some merits, 
this was not believed by the council to be the optimal solution at the current stage of 
development of health research in ireland.
however, there is a strong case for a single funding awarding agency for health 
services research and for science for health research to ensure consistency in 
assessments of the quality and relevance of research proposals and in terms of 
expertise and efficiency. the health Service executive and the health information 
& Quality authority need to determine their key research priorities and to decide 
whether they should develop their own capacity for commissioning research or use 
the expertise of the health Research Board, the latter being the option favoured by 
the council.
Setting Research and 
Funding priorities
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Funding: Recommendations
Resources for health research in ireland need to be significantly increased to build 
ireland's reputation for excellence in health research attracting the best people into 
the health system and the best companies to do research here. to maximise the 
impact of health research funding on the health system and the economy, the remits 
and focus of each of the agencies funding health research need to be transparent 
and a coordinated and coherent funding strategy adopted. detailed investment 
requirements and funding priorities are to be defined by the health Research group 
on health Research based on advice provided by the proposed expert group6.
R5 Funding for health research should be increased in line with that in similar 
benchmarked health systems.
Responsibility: department of health and children, hSe, health Research group
there is a need for a transparent and efficient structure to be established by and 
accountable to the department of health and children for the promotion, funding 
and commissioning of health research covering all elements from biomedical and 
population health to translational and health services research, encompassing the 
roles of the health Service executive, the health Research Board, and the health 
information & Quality authority.
Within this framework, the council recommends that the health Research Board's 
remit be expanded in the areas of infrastructure and training in addition to 
translational and clinical research and that its budget be increased substantially7 in 
order to build critical mass in these areas. the composition of the Board of health 
Research Board should be reviewed in the context of this expanded remit.
Significant increase 
in Funding
transparent and 
efficient Funding 
Structures
health Research 
Board Budget
6  the latest Oecd figures on health-related R&d expenditure in government budgets as a % of gdp showed that ireland spent 
0.015% (2002 data), compared with an eU average of 0.043% (2001 data) and an Oecd average of 0.121% (2003 data). it is 
noteworthy that countries like Finland, the UK and the USa which would be regarded as highly successful in terms of health research 
had % spends of 0.068%, 0.104% and 0.256% respectively. Source: Oecd Science, technology & innovation Scoreboard 2005.
7  detailed investment plan to be drawn up by the health Research group with advice from the expert group.
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the council also recommends that the health Service executive should encourage, 
facilitate and support health research with an appropriate level of funding. it 
recommends that the health Service executive and health information & Quality 
authority define their strategic priority research areas. these should be in line with 
national funding priorities identified by the idc health Research group with the 
expert advisory group and that relevant funding programmes be developed and 
administered by the health Research Board on their behalf.
R6 department of health and children to develop a transparent, coherent and 
efficient structure for the promotion, funding and commissioning of health 
research in between hRB, hSe and hi Qa.
Responsibility: department of health and children
hSe and hiQa 
Funding administered 
by hRB
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the council recommends that Science Foundation ireland's remit should expand to 
include certain aspects of translational research of relevance to its mission and  
funded projects. Science Foundation ireland currently funds translational research up 
to the point where human involvement is required. it is proposed that the Science 
Foundation ireland remit be expanded to include funding for the collection of samples 
and certain invasive human studies.
R7 expand the remit of Science Foundation ireland to include certain aspects of 
translational research.
Responsibility: Science Foundation ireland 
the council also strongly recommends that funding agencies develop joint strategies 
and hold joint calls for proposals in areas of mutual interest, overlap or synergy. it 
views this as an essential element of a coherent inter-agency approach to providing 
seamless funding from basic research through to clinical research and implementation.
Specifically, the council recommends that Science Foundation ireland and the health 
Research Board jointly fund translational research initiatives, led by hospital-based 
academic departments in collaboration with relevant university-based basic scientists.
the council also recommends that agencies currently engaged in joint calls – for 
example, the health Research Board with the medical research charities, the Wellcome 
trust and the health Service executive should be encouraged to continue this practice.
the european Union’s new Seventh Framework programme (Fp7) for research will 
be launched at the end of 2006 and will contain a significant increase in funding 
for health and health related research. Fp7 will provide a valuable mechanism for 
networking the burgeoning irish biological and molecular medicine research base with 
research teams and centres of excellence internationally and also provide a source of 
additional funding for research in areas of national interest.
expansion of 
SFi Remit
Joint Strategies 
and Joint calls
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in addition, internationally, foundation and philanthropy funding of health research 
has made a significant contribution. the council recommends that such funding 
be actively promoted.
R8 Research funding bodies to further develop joint strategies and hold joint calls 
and co-fund health research initiatives to ensure continuity of research from 
bench to bedside. Fully exploit the potential for international networking and 
leveraging funding for health research under the eU’s Seventh Framework 
programme for Research, 2007-2013. actively promote foundation and 
philanthropy funding for health research.
Responsibility: health Research Board, Science Foundation ireland, enterprise 
`ireland, ida, higher education authority, department of agriculture & Food, 
Medical Research charities
all funding for health research should be allocated on the basis of excellence and  
peer review together with relevance to ireland’s population and enterprise priorities. 
For industrial research and commercially relevant translational research, assessments 
should be complemented with additional strategic information on ipR, regulatory, 
marketing and manufacturing reviews as appropriate to ensure that the outcomes of 
research reach patients in a timely manner.
R9 allocate funding on the basis of excellence, as endorsed by peer review,  
and relevance.
Responsibility: all funding agencies
criteria for Funding: 
excellence and 
peer Review
Foundation and 
philanthropy Funding
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3.4 hUMan capital, edUcatiOn and inFRaStRUctURe
human capital: challenges
if the level of translational, clinical and other health research in ireland is to be 
increased significantly, the number of researchers will have to increase throughout 
the health research system. the increase in the number of health researchers needs 
to be achieved in tandem with an increase in the numbers entering medical training 
– to ensure the continued output of clinicians and nurses to meet the needs of the 
health sector. this will require measures and incentives that will make it both possible 
and attractive for health professionals to pursue research careers – such measures will 
include adequate training, attractive career structures and protected time for research.
Within the hospitals in particular, there are not enough health professionals engaged 
in research. this is a key challenge faced by the health Services executive. it needs 
to increase the number of clinical researchers, clinical research nurses, allied health 
researchers, study coordinators, technical staff, biostatisticians, bioinformaticians, data 
managers and administrative staff. capability also needs to be built in key disciplines 
such as epidemiology, genomics and proteomics. there is a critical need to develop 
capacity in the social and behavioural sciences including (but not confined to) health 
psychology, health economics, anthropology and sociology.
the shortage of researchers in hospitals is due, partly to the lack of research policies 
and strategies, and, in the case of consultants, partly to issues relating to consultant 
contracts, which do not generally provide protected time for research. in addition, the 
demands of clinical practice are such that even those with protected time for research 
often have difficulty using this time exclusively for research.
More Researchers 
needed
lack of Research 
Strategy
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human capital: Recommendations
in line with the recommended increase in funding for health research, the council 
recommends that increased numbers of clinicians be recruited with protected time for 
research. in the short term, the council proposes that 30 world class clinical Scientist-
led research teams in health research be hired without delay, across the spectrum of 
health research – from fundamental biomedical research, translational research and 
population health. the ramping up of human capital in the health research system 
should be sustained over the period up to 20138. in the hospital setting, these 
individuals should have eight protected sessions for research.
appointments should be made in complementary areas of investigation in line with 
strategic national priorities. the council recommends that the academic consultant 
contract, jointly issued by the hospital and the university, with protected time for 
research, should be used to engage clinician researchers. the people appointed should 
have defined appointments in relevant academic departments.
the council also recommends that the new consultant contract currently under 
negotiation, should recognise the crucial role of health research, and allow protected 
sessions for research for fixed periods of time. protected time for research should be 
available on a competitive basis to all clinicians as part of hospital human resource 
strategies. the council recommends that the university based academic departments 
of clinical disciplines, such as Medicine, should oversee the research portfolio 
(including consultant sessions) in teaching hospitals and that productivity and 
excellence are evaluated and suitably rewarded as intrinsic components of appropriate 
joint appointments.
8  Specific numbers to be developed by the health Research group, with advice of the expert group, in line with the national Strategy 
on Science, technology and innovation. http://www.entemp.ie/publications/science/2006/sciencestrategy.pdf
Recruit 
Researchers now
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in addition, the council recommends that more nurses, allied health professionals 
and epidemiologists are hired, also with protected time for research. Other research 
support staff including study coordinators, biostatisticians and bioinformaticians, social 
and behavioural scientists, data managers and administrative staff also need to be 
made available to support increased research performance. Where the employment 
of specialised staff cannot be justified in particular teams, the council recommends 
building a centralised pool of resources that can be made available as needed.
R10 Recruit increased numbers of clinicians with protected time for research.
 Recruit increased numbers of nurses, allied health professionals, 
epidemiologists, social and behavioural scientists with protected time for 
research. ensure that other research support staff are available.
Responsibility: health Service executive, hospitals, Universities
appointment of additional staff should be of sufficient scale to ensure service delivery 
is not compromised by affording health professionals protected time for research.
to satisfy the need for additional trained and experienced staff, the council 
recommends that the necessary facilities, career structures and other incentives are  
put in place to make clinical research an attractive option. this will be particularly 
necessary to attract clinical researchers from other countries to come to ireland.
R11 devise a range of incentives, including attractive career structures to attract 
both clinical and non-clinical staff to pursue research careers. in particular, 
efforts should be made to attract researchers from abroad in key areas where 
ireland is seeking to build a critical mass of excellent research.
Responsibility: health Service executive, hospitals, Universities,  
health Research group
Research Support
incentivise Research
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education of health professionals: challenges
the irish education and training system for medical staff does not adequately 
prepare medical graduates for a research career or for working with industry – this 
situation needs to change. as the health Research group identifies the priority areas 
for research, there will be a requirement for adequate numbers of suitably trained 
staff to work in those areas. Similarly while the majority of medical graduates with 
aspirations to be consultants have trained abroad as a result of inadequacies in post-
graduate training here, this is not part of a structural approach to post-graduate 
medical training. international mobility should be a central part of irish post-graduate 
medical training, in particular to deepen the connections with international health 
research centres of excellence.
Specifically, the curricula of all phases of medical education need to be revised to 
incorporate experience in conducting research. also, a number of postgraduate courses 
need to be made available to existing medical staff to facilitate the development of 
research capability.
the recent Buttimer Report on postgraduate Medical training9 recommends that the 
training bodies should include research as a core element of all postgraduate medical 
programmes and engage closely with the university/medical schools in planning 
and delivering the curriculum for research. the report also recommends that the 
health Service executive fund medical graduates to complete Md or phd programmes 
and that the hSe fund the hRB to establish phd programmes for medical graduates 
who want to pursue careers as clinician scientists. the primary purpose of the phd 
programmes is to develop clinician-scientists with a firm commitment to careers in 
biomedical research and academic medicine.
the Fottrell Report on Undergraduate Medical education10 also emphasises the need 
to ensure that undergraduate medical training provides graduates with exposure to 
research methodologies and an understanding of the impact of research on medicine.
9  the Report of the postgraduate Medical education and training group (2006), chaired by dr Jane Buttimer.
10  Report of the Working group on Undergraduate Medical education and training (2006) chaired by prof pat Fottrell.
inadequate 
Research exposure
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education of health professionals: Recommendations
the council recommends that, in line with the Buttimer and Fotrell reports, the 
curricula of all phases of medical education are revised to incorporate experience in 
conducting research, and postgraduate training should be made available to existing 
medical staff to facilitate the development of research skills.
Summer research experience, including experience in overseas laboratories, should be 
an integral part of the medical school curriculum. awareness raising activities should  
also be considered at secondary school level, including for example, initiatives  
where active scientists visit schools to raise awareness of the role and importance of 
health research.
Specifically, the council recommends that undergraduate and postgraduate medical 
training incorporate exposure to research methods and experience conducting research 
and that a number of new courses be introduced perhaps including a combined MB 
phd similar to the US and UK models, postgraduate courses in translational research 
and clinical epidemiology, nursing research methodology courses and cross-disciplinary 
programmes. courses should be provided by universities in association with the 
professional bodies. the precise repertoire of courses should be considered as part of 
the strategic approach to research planning outlined above.
the council also recommends the introduction of dedicated postgraduate academic 
clinician training tracks and the inclusion of research in continuing professional 
development programmes for physicians.
developing 
Research Skills
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the council recommends that medical schools collaborate in the development of 
existing and new undergraduate and postgraduate courses to ensure delivery to the 
highest international standards and that international mobility is an integral part of 
these programmes.
R12 Undergraduate and postgraduate medical training to include exposure to 
research methods and experience.
 new courses to be introduced including: MB phd; postgraduate courses in 
translational research; clinical epidemiology; nursing research methodology; 
and cross-disciplinary studies.
 Medical schools to collaborate in the development of undergraduate and 
postgraduate courses to ensure delivery to the highest international standards.
 international mobility, supported by the health Service executive, to be an 
integral part of these programmes.
 establish a national graduate school in translational medicine linked to a 
network of clinical research centres.
Responsibility: Medical Schools in conjunction with universities, hospitals and 
training bodies
R13 develop postgraduate training tracks for academic clinicians and continuing 
professional development for physicians.
Responsibility: Medical Schools in conjunction with universities and hospitals
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infrastructure and Facilities: challenges
the department of health and children's 2001 strategy document, Making Knowledge 
Work for health identified clinical research centres (cRcs) as a key infrastructure need. 
there are now four such centres either operational or planned – with Beaumont/
RcSi and St. James’s having capacity to do clinical trials and those in St. vincents 
and Matter hospitals specifically funded to collect and store biological samples. 
cRcs provide the facilities needed to support patient focused research studies and 
also contribute to postgraduate research training of health professionals and to the 
continuing professional education for all health researchers.
however, the deficit in health research infrastructure in ireland is such that these four 
centres are unlikely to address all the research infrastructure needs evident within 
the irish health system. a more wide ranging investment is required together with 
a broader definition of the role that cRcs can play in improving healthcare through 
research. additional clinical/translational research centres need to be established to 
position the island of ireland as a competitive research network. it will therefore be 
important that research strengths and facilities across all centres are complementary 
and that operational procedures and information systems are harmonised. in the 
context of developing their recommendations on ireland's health research priorities, 
the proposed expert group will need to look at what infrastructure and research 
competencies are developed in each location.
as well as building a network of clinical/translational research centres, requirements 
for access to a range of other facilities have also been identified; these include: 
animal facilities, bio-banks and gene libraries, imaging facilities, databases, 
bioinformatics and computing capability, a comprehensive index of current clinical 
research, integrated electronic medical records and a unique patent identifier.
Further investment 
in clinical Research 
capacity necessary
Other infrastructural 
deficits
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the development of a unique patient identifier (Upi) could bring enormous potential 
benefits in the context of health research. a Upi is a means of uniquely identifying 
individuals across the entire healthcare system, enabling access to patient information 
from multiple locations, and so ensuring continuity of care. it can also contribute to 
epidemiological research by assisting in the study of the patterns, causes, and control 
of disease in populations.
there are, however, some issues around the adoption of a Upi as a standard. While 
complete and accurate disclosure of information by the patient is critical to quality 
health care, this must be in the context of appropriate provisions to ensure integrity 
of the Upi information and to protect against unauthorised uses and disclosures. it 
is essential for outcomes monitoring and assessment that such information can be 
used for audit, to evaluate the effectiveness of services and for research, e.g. cancer 
registration is used to evaluate how good cancer services are. 
For these reasons and given the genuine concerns of patients about the use of their 
personal information for research, extensive consultation with stakeholders and the 
general public will be necessary before a Upi is introduced.
development of Unique 
patient identifier for 
irish health Service
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infrastructure and Facilities: Recommendations
Significant investment in infrastructure in ireland is required to strengthen the 
capacity of the academic and health system to facilitate increased research of the 
highest quality by the academic community, to support a critical mass of clinician 
scientists, to attract industry to conduct collaborative research and to place research at 
the heart of the training of healthcare professionals.
the council recommends that the required additional investment needed to fill the 
physical infrastructure gaps in translational and clinical research including further 
clinical/translational research centres in major academic hospitals, bio-banking 
facilities, a gene-library and imaging and animal testing facilities be prioritised  
by the expert group as part of developing and advising on strategic national  
research priorities.
the council recommends that the health Research group should determine the 
requirements for strengthening information and communications technology (ict) 
infrastructure throughout the island of ireland to provide leading edge bioinformatics 
and computing capability, comprehensive research and data management systems, a 
database of current clinical research, an integrated electronic medical records system 
and a Upi. 
the health Research group should determine the investment in the ict and health 
information infrastructure necessary to support internationally competitive health 
services and population health research.
investment in 
infrastructure
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R14 develop a research investment plan setting out the immediate additional 
investment required in key infrastructure to facilitate effective translational 
research and the infrastructural investment requirements to address strategic 
national priorities.
 prioritise the introduction of an integrated electronic medical records system 
and unique patient identifier, based on appropriate public consultation.
Responsibility: health Research group
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3.5 innOvatiOn, RegUlatORY aFFaiRS  
and tRanSlatiOn
innovation: challenges
Until recently, hospitals regarded research as a fairly minor part of their brief. even 
today, few hospitals in ireland consider research to be core to their mission, and few 
have a research strategy. as a result, intellectual property (ip) issues are not widely 
understood by the clinical research community, and hospitals generally do not have 
systems in place for identifying, protecting and exploiting ip.
Measures need to be taken to ensure that health research produces innovation and 
that ip is identified, protected and exploited.
there is currently evidence of research projects in the drug and medical device 
development areas getting to the point where pre-clinical and clinical research needs 
to be done, but due to obstacles to doing it in ireland, this further research is being 
done abroad.
a vibrant health research system depends on the support of the enterprise sector,  
and commercialisation of research with an industrial partner is often the most  
efficient way of getting the benefits of health research to the patient -in ireland 
and in other countries. hospital research strategies should therefore focus on 
establishing clear links with industry to enable commercialisation of innovative and 
beneficial product ideas. in addition to ensuring that the latest findings are translated 
to improved human health and to providing the best possible care to patients, 
commercialisation of research ensures returns to the national economy, providing 
quality of life and better jobs.
if intellectual property generated in ireland has application in other countries, there 
may be significant opportunities for commercialisation. While the financial returns 
from ireland – with its relatively small population – may be limited, the returns from 
the global market could be very substantial.
Research Strategy and 
intellectual property
linking with 
industry
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Research Strategy
ip policies and 
procedures
innovation: Recommendations
the council recommends that research should be a key pillar of hospitals' missions 
and that each academic teaching hospital should have a research strategy, including 
ring-fenced funding for research provided by the health Service executive.
R15 Research to be a clearly stated component of the mission of academic teaching 
hospitals and of the health Service executive.
 each teaching hospital to have a research strategy.
Responsibility: teaching hospitals, health Service executive, health  
Research Board
to promote effective translation of research findings into technologies and  
treatments for patient benefit, the council recommends that hospitals develop ip 
policies and procedures, modelled on those in place in the universities, to deal 
explicitly with the management of ip and arrangements for exploitation and 
commercialisation. a key part of an ip policy is to ensure clarity on institutional 
ownership of ip arising from publicly funded research. policies should also outline 
how royalties and equity based commercialisation income will be distributed, 
including details of incentives for inventors. post-graduate training in the medical area 
should also include modules on intellectual property management, best practice in 
confidentiality, entrepreneurship, etc.
in particular, the council recommends that the new consultant contract should make 
it clear that any ip generated by a consultant using public funds is owned by the 
institution employing the consultant, in line with national policy and as set out in the 
national codes of practice11. in the case of academic-clinical appointments, where an 
investigator may have multiple affiliations, clarity on ownership of future ip arising 
11  national code of practice for the Managing intellectual property from publicly Funded Research (icSti, april 2004) and  
national code of practice for Managing and commercialising intellectual property from public-private collaborative Research  
(aSc, november 2005).
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from a research grant should be established in writing, ideally before the  
submission of a grant application to the relevant funding agency or agencies.  
Funding agencies should ensure that their assessment procedures mandate this 
information on submission.
R16 institutional ownership of ip arising from publicly funded research to be 
asserted through hospital policies and consultant contracts.
 Responsibility: employer – health Service executive/hospitals  
and/or Universities
the council recommends that, in the short term, research offices be created in the 
academic hospitals12, and these should work closely with the technology transfer 
offices in the universities – which are relatively well established – to ensure that 
hospital ip is adequately protected and optimally exploited. the hSe and enterprise 
ireland need to agree an approach for the other non-aligned hospitals. enterprise 
ireland can help by providing standard document and guidelines, training and by 
helping to build necessary connections. a central resource, providing specialised 
technology transfer expertise in the medical field should be established by enterprise 
ireland and made available to all hospitals through the universities.
With regard to maximising the translation of health-related research into new 
products and services, the council recommends that enterprise ireland also establish  
a central portal to facilitate industry, academic, hospital collaboration and as a  
means of brokering links between technology providers and potential 
commercialisation partners.
12  enterprise ireland has recently launched a call for proposals to strengthen technology transfer offices in higher education 
institutes. this call is open to academic teaching hospitals.
technology transfer
central portal 
for collaboration
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Research in 
primary care
R17 a number of actions are required to promote the commercialisation of health 
related research. hospitals to establish procedures to capture, protect and 
exploit intellectual property.
 hospitals to work with technology transfer offices in affiliated universities to 
make best use of available capabilities and to exploit ip optimally.
 enterprise ireland to provide additional technology transfer expertise in  
health, pharmaceutical and medical technology research – to hospitals through 
the universities.
 a central portal to facilitate industry, academic, hospital collaboration to  
be established.
Responsibility: hospitals with University technology transfer offices and 
enterprise ireland
the council recognises that the majority of clinical encounters in ireland occur 
in primary care. it is also recognised that the health of the irish population is 
fundamentally influenced by social and economic factors that operate outside the 
health system. thus there is a clear need to develop the infrastructure to sustain a 
flourishing, innovative and internationally competitive research culture in primary care 
and population health.
R18 Foster innovation and excellence in primary care, health services and 
population health research.
Responsibility: health Service executive
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While the importance of health research is often recognised by patient groups with 
particular interests and who can see the benefit of new discoveries, and the health 
Research Board has a long standing commitment to raising awareness about health 
research, the general public is not fully aware of the importance of research in 
improving health service delivery, patient care and overall wellness of the population. 
the council recommends the introduction and resourcing of outreach initiatives to 
raise awareness of the value of research in addressing short-term issues relating 
to services delivery and emphasising the longer-term health and well being of the 
population, importance of the role of industry in the translation of research outcomes 
into innovative products and therapies. there is also a need to place increased 
importance on outreach activities under all publicly funded health research and to 
provide further training for scientists in communication of scientific issues to the 
general public. Outreach and commercialisation need to be addressed at a project-
level, at the hospital-academic level and by funding agencies.
R19 Outreach initiatives to be introduced to raise awareness of the importance 
of research in improving health service delivery, patient care and population 
health and the role of industry in timely translation of research outcomes to 
innovative products and therapies.
Responsibility: health Service executive, hospitals, Universities,  
health Research Board
Outreach activities
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Regulatory affairs: challenges
ireland is currently uncompetitive as a location for conducting clinical trials and is 
losing trials to other countries. a number of factors are taken into consideration when 
a company selects a location to conduct a clinical trial; the most important of these is 
the time it takes to get the trial up and running. currently, establishing clinical trials 
in ireland takes too much time, and one of the major causes of this is inefficiency in 
the ethical approval process.
there are currently thirteen different ethics committees approved by the department 
of health and children. each of these has different operating procedures, 
membership of these committees is voluntary, and no formal training is provided 
to members. ireland’s relative attractiveness for clinical trials is being eroded as 
many other countries with which we compete for health-related research used the 
implementation of the eU clinical trials directive as an opportunity to fundamentally 
restructure their ethics committees.
While the regulations in ireland do allow researchers to apply in parallel for regulatory 
approval by the irish Medicines Board and for approval by the relevant ethics 
committee, this is not the uniform practice currently. in the case of multi-centre 
clinical trials, a single ethics committee opinion from a recognised ethics committee 
is required, and that opinion prevails at all centres. in practice, there is often an 
additional step, where the trial sponsor must also obtain permission from each of the 
individual hospitals. this can further extend the significant delay in starting a trial.
the problem is compounded by the shortage of clinical research nurses, which can 
result in delays of five to six months. in an industry where timing is critical, this is a 
major issue.
the regulatory and ethical approval processes need to be reformed to dramatically 
reduce the time it takes to get a clinical trial up and running. Key aspects of this 
reform are reducing the number of ethics committees, increasing their operational 
efficiency. parallel review by the iMB and relevant ethics committee requires to be 
standard practice in all cases. 
Review of 
clinical trials
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electronic Submission 
and parallel Review
Regulatory affairs: Recommendations
the council recommends that the number of ethics committees be streamlined and 
consolidated to four regional ethics committees, from thirteen currently. Under the eU 
directive on clinical trials, the Minister and the department of health and children are 
the designated authority for regulating ethical review of clinical trials in ireland. the 
department of health and children should arrange to have a coordination mechanism 
in place in relation to its functions in this area, that brings together the various ethics 
approval processes, and ensures that there is clarity, transparency and consistency in 
the national approach for enterprises and academics wishing to conduct a trial.
the council advocates that the functioning of the committees should be 
professionalised and that members should be paid. it also recommends that members 
receive formal training, that all committees should work to common standard 
operating procedures and should have a well resourced secretariat.
While the large majority of clinical trials in ireland tend to be pharmaceutical trials, 
smaller numbers of trials are also conducted in other sectors including medical 
diagnostics and devices, nutritional products, drug delivery, combination drug-device 
products and combination medicines for example. Recognising that these different 
types of trials may require specialist input into trial design and ethical approval the 
council recommends that appropriately trained sector specialists be appointed to the 
regional ethics committees and that these members be available to serve on other 
ethics committees as required accommodating the need for additional expertise.
the council recommends that ethical reviews of protocol applications should be 
assessed in parallel with reviews by the irish Medicines Board and that appropriate 
infrastructure be put in place to enable electronic submissions for regulatory and 
ethical approval.
Streamlining and 
consolidation of 
ethics committees
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R20 Streamline and consolidate ethical approval structures to four regional ethics 
committees, with professional paid members, sectoral specialists, standard 
operating procedures and well resourced secretariat.
 department of health and children to establish a coordination mechanism for 
this revised ethics committee structure and this should be the first contact 
point for enterprises and academics wishing to conduct a trial. 
 enable electronic submissions of applications for clinical trails approvals with 
parallel review by the irish Medicines Board and ethics committees as  
standard practice.
Responsibility: department of health and children, irish Medicine Board
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promoting and developing capability in translational Research: challenges
the council has identified an opportunity for ireland to position itself as a key player 
in the translational medicine area – that is, at the convergence of fundamental 
biomedical research and clinical research. translational medicine has the potential to 
transform healthcare delivery, with enormous economic and social benefit. as with 
clinical trials, ireland is losing out on significant investments due to deficiencies in 
translational research capabilities.
ireland has invested heavily in fundamental bioscience, and has significant research 
activities in several related fields that offer potential health benefits (for example, 
diagnostics, medical devices, pharmaceuticals, marine resources, agriculture and food). 
the country also has a significant enterprise base in several of these areas, including 
foreign-owned multinational corporations and indigenous companies, some of whom 
are established as world leaders in their particular niches.
the benefits of this investment can only be realised through the translation of 
the resulting knowledge into new diagnostics and therapeutics, leading to better 
healthcare. investment in translational medicine is therefore a logical progression 
in national strategic development initiatives and has the potential to deliver 
significant economic benefit to ireland in terms of strengthening indigenous industry 
and attracting further foreign direct investment. the establishment of a vibrant 
translational research environment is a prerequisite to attracting pharmaceutical and 
medical technology R&d activities to ireland.
next generation therapies (monoclonal antibody, stem cell and gene-based) will  
be extremely expensive. it is clear that ireland will be unable to exploit these 
therapies and strategies without being part of a development process through 
translational research.
Some 30 members of the irish Bio-industry association are already involved in 
healthcare-related activities, and many of them are interested in gaining access to the 
facilities or intellectual property that may become available within the health service.
potential of 
translational Medicine
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Other countries have already recognised this opportunity – for example, Singapore 
and Scotland, england and Wales are investing substantial resources in health research 
and have developed infrastructure for basic and translational research. in the US, 
the national institute of health (nih), which invests more than $28 billion annually 
in medical research, is moving beyond the model of clinical research centres (cRcs) 
to large-scale, translational research facilities. it has recently issued a call for the 
establishment of translational research facilities, with a typical budget of $100 million 
per centre.
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promoting and developing capability in translational Research: 
Recommendations
the changes recommended in this report will help to develop a health research 
system in ireland where it is efficient and easy to conduct translational research, and 
will enable ireland to become a significant player in translational medicine. however, 
while these actions are necessary as a first step in a process, they are not sufficient to 
differentiate ireland as a leading location for conducting translational research.
the council recommends that ida ireland, enterprise ireland, and other funding 
agencies, together with the idc health Research group and the expert advisory 
group work with their existing and potential clients of other state bodies to examine 
how best to position ireland as an attractive location for translational research, and 
investment and policy requirements, such as animal facilities, clinical research centres, 
expertise etc.
however, there is significant competition and a limited window of opportunity for 
ireland to establish itself as a player in the translational research space. identification 
of opportunities to position ireland as a location of choice for translational research 
and their incorporation into the national strategy should be pursued as a matter  
of urgency.
R21 identify the specific areas of translational research where ireland can develop a 
leading position and the actions required to differentiate ireland as a location 
of choice for translational research.
Responsibility: ida ireland, enterprise ireland, hRB, health Research group
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